Apyx Medical Inc
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +0.34%.
Did APYX Beat Earnings? Q4 2025 Results
Apyx Medical closed out fiscal 2025 on a strong note, delivering a Q4 that beat Wall Street expectations on both the top and bottom lines as the commercial momentum behind its AYON Body Contouring System continued to build. The company posted revenue of $19.16 million for the quarter, a 34.8% increase year-over-year that edged past the $18.54 million consensus estimate by 3.35%, while its net loss of $0.03 per share came in well ahead of the $0.06 loss analysts had anticipated, a 46.43% positive surprise. The primary engine behind the outperformance was the Surgical Aesthetics segment, which grew 38.1% year-over-year to $16.71 million following AYON's September 2025 commercial launch, with U.S. sales alone surging nearly 50%. Adjusted EBITDA turned positive at $689,000, a meaningful inflection from a $2.20 million loss a year earlier. Looking ahead, management guided fiscal 2026 total revenue of $57.50 million to $58.50 million, with Surgical Aesthetics expected to carry the bulk of growth as a potential mid-2026 FDA clearance for AYON's power liposuction label expansion could further broaden the system's commercial reach.
- Commercial launch of AYON Body Contouring System in September 2025 driving U.S. Surgical Aesthetics sales growth of nearly 50%
- Strong international generator sales contributing to Surgical Aesthetics growth
- Disciplined cost management keeping operating expenses flat year-over-year in Q4
- Favorable segment mix shift toward higher-margin Surgical Aesthetics
“We are making steady progress scaling the U.S. commercial program for AYON following its official launch in September 2025, with early customer interest and order activity continuing to exceed our internal expectations. This momentum contributed to more than 38% growth in our Surgical Aesthetics segment, including a nearly 50% increase in the U.S. market.”
Apyx Medical CEO, on the earnings call
Forward Guidance & Outlook
For fiscal year 2026, Apyx Medical expects total revenue in the range of $57.5 million to $58.5 million, compared with $52.8 million in 2025. Surgical Aesthetics revenue is expected to be $53.0 million to $54.0 million (versus $45.3 million in 2025), while OEM revenue is expected to be approximately $4.5 million (versus $7.5 million in 2025). Operating expenses are expected to remain below $45.0 million. The company anticipates potential 510(k) clearance for AYON label expansion to include power liposuction in mid-2026. Management believes cash runway extends through 2027 based on AYON uptake projections, working capital management, and cost controls.
APYX YoY Financials
APYX Revenue by Segment
APYX Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.